Register
Medicines reference
Product

Excegran

Zonisamide · Sanofi

1 form: capsule. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Used for: Epilepsy

Form Species Dose Frequency Georgia
100 mg, Capsule · Cat Cat No dose for this species
No cat dose: no consensus, label or clinical study gives a zonisamide dose for cats; a hypersensitivity syndrome has been reported in a cat.
- Georgia Yes, human
In force until 04 Jan 2027
Human (Ministry of Health, RAMA)
In the register: ექსცეგრანი 100მგ კაფსულა - #100
№ რ/ა-P-0106
Verified on: 29 Oct 2026
100 mg, Capsule · Dog Dog 3–7 mg/kg
Off-label substance bridge: a human zonisamide product; dose from Core zonisamide (IVETF 2015), same substance and route. Epilepsy: 3-7 mg/kg every 12 hours (7-10 mg/kg with phenobarbital). The 100 mg capsule is given whole; check tear production (sulfonamide).
· every 12 hours
every 12 hours Georgia Yes, human
In force until 04 Jan 2027
Human (Ministry of Health, RAMA)
In the register: ექსცეგრანი 100მგ კაფსულა - #100
№ რ/ა-P-0106
Verified on: 29 Oct 2026
Details: pack, label wording, sources, registration

Excegran 100 mg, Capsule

capsule, human medicine
Composition / strength
Zonisamide100 mg
Formulation Type
Capsule
Administration route
By mouth
Manufacturer
Sanofi · France
Registration
Georgia Yes, human
In force until 04 Jan 2027
Human (Ministry of Health, RAMA)
In the register: ექსცეგრანი 100მგ კაფსულა - #100
№ რ/ა-P-0106
Verified on: 29 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
No dose for this species
No cat dose: no consensus, label or clinical study gives a zonisamide dose for cats; a hypersensitivity syndrome has been reported in a cat.
Cat Any weight By mouth -
IVETF 2015
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe
BMC Veterinary Research 11:176, 2015
3–7 mg/kg
Off-label substance bridge: a human zonisamide product; dose from Core zonisamide (IVETF 2015), same substance and route. Epilepsy: 3-7 mg/kg every 12 hours (7-10 mg/kg with phenobarbital). The 100 mg capsule is given whole; check tear production (sulfonamide).
Dog Any weight By mouth every 12 hours
IVETF 2015
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe
BMC Veterinary Research 11:176, 2015
From the active substance's dose: the label does not cover this species; off-label for this pack.

Known Contraindications

  • Warning
    Zonisamide is a sulfonamide: keratoconjunctivitis sicca and polyarthropathy have been reported - check tear production. Sedation, ataxia, vomiting and inappetence are common; titrate up. Phenobarbital increases its clearance by about half; caution with other carbonic anhydrase inhibitors.
    Sources: ACVIM · JVIM
  • Warning (Cat)
    Cat: suspected zonisamide hypersensitivity syndrome (generalised lymphadenopathy, hyperglobulinaemia, cytopenias) resolved only after zonisamide was stopped.

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.